- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Snapshot for Zalicus Inc (ZLCS)
| Open: | 6.1000 | Day's Range: | 6.0600 - 6.8000 | Volume: | 1,042,554 |
|---|---|---|---|---|---|
| Previous Close: | 1.2000 | 52wk Range: | 0.4300 - 6.8000 | 1-Yr Rtn: | +49.29% |
Key Statistics for ZLCS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.8000 |
| Est. EPS (USD) (12/2013) | -1.8000 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 161.86 |
| Shares Outstanding (M) | 22.48 |
| 30 Day Average Volume | 725,109 |
| Price/Book (mrq) | 8.4025 |
| Price/Sale (ttm) | 8.9447 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Dividend Ex-Date | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 11/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ZLCS
Company Profile & Key Executives for ZLCS
Zalicus Inc is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The Company's drug pipeline includes an arthritis formula in phase 2 development.
| Mark H N CorriganPresident/CEO | Justin A RenzExec VP/CFO/Treasurer |
| Jason F ColeExec VP:Corporate Dev/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
Advertisement
-
ZLCS News
-
Industry News
Advertisement
Sponsored Links
Advertisements
Rate this Page